Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist Elagolix
Open Access
- 1 February 2009
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 94 (2) , 545-551
- https://doi.org/10.1210/jc.2008-1695
Abstract
Context: Parenteral administration of peptide GnRH analogs is widely employed for treatment of endometriosis and fibroids and in assisted-reproductive therapy protocols. Elagolix is a novel, orally available nonpeptide GnRH antagonist. Objective: Our objective was to evaluate the safety, pharmacokinetics, and inhibitory effects on gonadotropins and estradiol of single-dose and 7-d elagolix administration to healthy premenopausal women. Design: This was a first-in-human, double-blind, placebo-controlled, single- and multiple-dose study with sequential dose escalation. Participants: Fifty-five healthy, regularly cycling premenopausal women participated. Interventions: Subjects were administered a single oral dose of 25–400 mg or placebo. In a second arm of the study, subjects received placebo or 50, 100, or 200 mg once daily or 100 mg twice daily for 7 d. Treatment was initiated on d 7 (±1) after onset of menses. Main Outcome Measures: Safety, tolerability, pharmacokinetics, and serum LH, FSH, and estradiol concentrations were assessed. Results: Elagolix was well tolerated and rapidly bioavailable after oral administration. Serum gonadotropins declined rapidly. Estradiol was suppressed by 24 h in subjects receiving at least 50 mg/d. Daily (50–200 mg) or twice-daily (100 mg) administration for 7 d maintained low estradiol levels (17 ± 3 to 68 ± 46 pg/ml) in most subjects during late follicular phase. Effects of the compound were rapidly reversed after discontinuation. Conclusions: Oral administration of a nonpeptide GnRH antagonist, elagolix, suppressed the reproductive endocrine axis in healthy premenopausal women. These results suggest that elagolix may enable dose-related pituitary and gonadal suppression in premenopausal women as part of treatment strategies for reproductive hormone-dependent disease states.Keywords
This publication has 27 references indexed in Scilit:
- Discovery of Sodium R-(+)-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (Elagolix), a Potent and Orally Available Nonpeptide Antagonist of the Human Gonadotropin-Releasing Hormone ReceptorJournal of Medicinal Chemistry, 2008
- Non-Peptide Gonadotropin-Releasing Hormone Receptor AntagonistsJournal of Medicinal Chemistry, 2008
- Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormoneNature Clinical Practice Endocrinology & Metabolism, 2007
- Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic painFertility and Sterility, 2006
- Gonadotropin-releasing-hormone-receptor antagonistsThe Lancet, 2001
- Dose-related suppression of serum luteinizing hormone in women by a potent new gonadotropin-releasing hormone antagonist (Ganirelix) administered by intranasal sprayFertility and Sterility, 1997
- Gonadotropin-Releasing Hormone Antagonists: Effects on the Ovarian Follicle and Corpus LuteumClinical Obstetrics and Gynecology, 1993
- Hormone treatment of endometriosis: The estrogenthreshold hypothesisAmerican Journal of Obstetrics and Gynecology, 1992
- Gonadotropin-Releasing Hormone and Its AnaloguesNew England Journal of Medicine, 1991
- Hypophysial Responses to Continuous and Intermittent Delivery of Hypothalamic Gonadotropin-Releasing HormoneScience, 1978